FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage Breast Cancer By Ogkologos - June 17, 2026 214 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved two companion diagnostics for identifying patients for treatment with fam-trastuzumab deruxtecan-nxki Source RELATED ARTICLESMORE FROM AUTHOR Beginning Surveillance Colonoscopy After 5 Years from Removal of High-Risk Adenomas Non-inferior than at 3 Years in Terms of Cumulative CRC Incidence Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce MOST POPULAR The Lung Immune Prognostic Index May Indicate Response to Immune Checkpoint... December 9, 2020 Immunotherapy Drugs Expand Treatment Options for Advanced Lung Cancer April 27, 2018 Adding Atezolizumab to Chemotherapy Does Not Improve Outcomes in Patients Who... June 4, 2024 Cancer in My Community: Encouraging Cancer Screening in Estonia May 23, 2023 Load more HOT NEWS NHL Team Surprises Big Fan Who Spent Breast Cancer Treatment Performing... ctDNA-Guided Therapy with Pertuzumab plus Trastuzumab for HER2-Amplified mCRC ‘Inside Edition’ Anchor Thanks Viewer For Pointing Out Lump That Turned... Conducting Phase I Clinical Trials During the COVID-19 Pandemic
